FLGT
$15.43
Fulgent Genetics, Inc.
Intraday
Recent News
Fulgent Genetics (FLGT) Is Down 33.4% After 2025 Results And Oncology-Focused Expansion - What's Changed
Fulgent Genetics reported its 2025 results in the past, with revenue rising to US$322.67 million while the net loss widened to US$60.51 million, and it issued 2026 guidance calling for about US$350.00 million in revenue alongside ongoing investment in oncology and AI-enabled lab services. The company also closed acquisitions of Bako Diagnostics and StrataDx and advanced its cancer drug candidates and digital pathology platform, potentially reducing customer concentration risk and broadening...
A Look At Fulgent Genetics (FLGT) Valuation After 2025 Results And 2026 Revenue Guidance
Fulgent Genetics (FLGT) has sparked fresh attention after releasing full year 2025 results, reporting revenue of US$322.67 million and a net loss of US$60.51 million, along with 2026 revenue guidance of about US$350 million. See our latest analysis for Fulgent Genetics. The earnings release and 2026 revenue guidance have arrived alongside heavy selling pressure, with the 1 day share price return of 38.09% decline and year to date share price return of 40.09% decline, while the 5 year total...
Fulgent Genetics Inc (FLGT) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges
Fulgent Genetics Inc (FLGT) reports a 14% annual revenue increase, strategic acquisitions, and new market opportunities despite facing significant customer revenue loss.
Top Midday Decliners
Fulgent Genetics (FLGT) reported Friday Q4 sales below market expectations, and its forecasts for no
Fulgent Genetics Q4 Earnings Call Highlights
Fulgent Genetics (NASDAQ:FLGT) used its fourth-quarter and full-year 2025 earnings call to outline continued growth in its laboratory services business, accelerating investments in digital pathology and AI, and progress across its therapeutic development pipeline. Management also addressed a near-te